# US 2019/0167566 A1 · Pharmaceutical cream compositions of oxymetazoline and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167566 A1
- Document ID: US20190167566A1
- Status: Published application
- Kind: A1
- Application number: 16/267,590
- Filed: 2019-02-05
- Published: 2019-06-06
- Earliest claimed: 2011-02-15
- Assignees: Aclaris Therapeutics, Inc.
- Applicants: Aclaris Therapeutics, Inc.
- Inventors: Stuart D. SHANLER; Christopher POWALA
- Web page: https://patentgrep.com/patent/US20190167566A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/4164: 1,3-Diazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of treating erythema, telangiectasia or inflammatory lesions associated with rosacea comprising topically administering a pharmaceutical composition comprising a therapeutically effective amount of oxymetazoline or a pharmaceutically acceptable salt thereof, and about 1% to about 50% by weight of an emollient comprising medium chain triglycerides, diisopropyl adipate, oleyl alcohol, and lanolin.

### Claim 22 (depends on 21)

The method of claim 21, wherein the inflammatory lesions are selected from the group consisting of papules, pustules, cysts and phymas.

### Claim 23 (depends on 2)

The method of claim 2 1, wherein the pharmaceutically acceptable salt of oxymetazoline is oxymetazoline hydrochloride.

### Claim 24 (depends on 2)

The method of claim 2 1 , wherein the composition further comprises an additive selected from the group consisting of emulsifiers, preservatives, emulsion stabilizers, pH adjusters, chelating agents, viscosity modifiers, anti-oxidants, surfactants, emollients, opacifying agents, skin conditioners, buffers, and combinations thereof.

### Claim 25 (depends on 21)

The method of claim 21, wherein the composition further comprises a topically active pharmaceutical or cosmetic agent.

### Claim 26 (depends on 2)

The method of claim 2 5, wherein the topically active pharmaceutical or cosmetic agent is selected from a group consisting of an anti-rosacea agent, an antibacterial agent, an antimycobacterial agent, an anti-acne agent, an anti-parasitic agent, an antifungal agent, an steroidal anti-inflammatory agent, an non-steroidal anti-inflammatory agent, an anesthetic agent, an anti-pruriginous agent, an anti-free radical agent, an anti-seborrheic agent, an antipsoriatic agent, a tricyclic anti-depressant, an antihistamine, and a chemotherapeutic agent.

### Claim 27 (depends on 21)

The method of claim 21, wherein the oxymetazoline or the pharmaceutically acceptable salt thereof is in an amount of from about 0.0075% to about 5% by weight.

### Claim 28 (depends on 21)

The method of claim 21, wherein the oxymetazoline or the pharmaceutically acceptable salt thereof is in an amount of from about 0.0075% to about 3% by weight.

### Claim 29 (depends on 21)

The method of claim 21, wherein the oxymetazoline or the pharmaceutically acceptable salt thereof is in an amount from about 0.01% to about 2.5% by weight.

### Claim 30 (depends on 21)

The method of claim 21, wherein the oxymetazoline or the pharmaceutically acceptable salt thereof is in an amount from about 0.01% to about 2% by weight.

### Claim 31 (depends on 21)

The method of claim 21, wherein the oxymetazoline or the pharmaceutically acceptable salt thereof is in an amount from about 0.01% to about 1% by weight.

### Claim 32 (depends on 21)

The method of claim 21, wherein the oxymetazoline or the pharmaceutically acceptable salt thereof is in an amount of about 1% by weight.

### Claim 33 (depends on 21)

The method of claim 21, wherein the composition further comprises an additional therapeutic agent for the treatment of non-inflammatory manifestation of rosacea such as telangiectasias, erythema, epidermal barrier dysfunction, or other manifestation of rosacea.

### Claim 34 (depends on 33)

The method of claim 33, wherein the additional therapeutic is selected from the group consisting of a selective alpha-1 adrenoreceptor agonist, a selective alpha-2 adrenoreceptor agonist, a non-selective alpha-1 adrenoreceptor agonist, a non-selective alpha-2 adrenoreceptor agonist, and a combination thereof.

### Claim 35 (depends on 21)

The method of claim 21, wherein administration of the composition is in combination with another therapy directed toward the treatment of inflammatory lesions.

### Claim 36 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition comprises:
about 1.0% by weight oxymetazoline HCl; and
wherein a pH of the pharmaceutical composition is about 4.5 at room temperature.

### Claim 37 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition of further comprises an emulsifier including at least one of the following: polyethylene glycol stearate (PEG-6 stearate), polyethylene glycol 32 stearate (PEG-32 stearate), glycol stearate, cetostearyl alcohol, ceteareth-6, stearyl alcohol, and ceteareth-25.

### Claim 38 (depends on 37)

The method of claim 37, wherein the ratio of the emulsifier to the emollient is about 0.87:1.

### Claim 39 (depends on 37)

The method of claim 37, wherein the emulsifier further comprises about 2% by weight of macrogol (6) cetostearyl ether, and about 2% by weight of macrogol (25) cetostearyl ether.

### Claim 40 (depends on 37)

The method of claim 37, comprising PEG-6 stearate, PEG-32 stearate, and glycol stearate in a mixture comprising about 7% to about 8% by weight of the composition.

### Claim 41 (depends on 37)

The method of claim 37, wherein the cetostearyl alcohol comprises about 4% to about 8% by weight.

### Claim 42 (depends on 37)

The method of claim 37, wherein the ratio of the PEG-6 stearate, PEG-32 stearate and glycol stearate to the cetostearyl alcohol is about 1:1.

### Claim 43 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition further comprises a pH regulator selected from the group consisting of sodium citrate dihydrate, anhydrous citric acid, and a combination thereof.

### Claim 44 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition further comprises a preservative selected from the group consisting of methylparaben, propylparaben, phenoxyethanol, and a combination thereof.

### Claim 45 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition further comprises an antioxidant selected from the group consisting of vitamin B, nordihydroguaiaretic acid, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, erythorbate acid, sodium erythorbate, ascorbir palmitate, and ascorbir stearate, and a combination thereof.

### Claim 46 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition of further comprises a chelating agent selected from the group consisting of alanine, sodium polyphosphate, sodium methaphosphate, citric acid, phosphoric acid, tartaric acid, disodium edetate (EDTA), dihydroxyethyl glycine, derivatives thereof, salts thereof, and a combination thereof.

### Claim 47 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition further comprises a solvent selected from the group consisting of polyethylene glycol 300, water, and a combination thereof.

### Claim 48 (depends on 21)

The method of claim 21, wherein the pH of the pharmaceutical composition is about 4.5 at room temperature.

### Claim 49 (depends on 21)

The method of claim 21, wherein the emollient comprises about 7% by weight of medium chain triglycerides, about 7% by weight of diisopropyl adipate, about 7% by weight of oleyl alcohol, and about 2% by weight of lanolin.

### Claim 50 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition further comprises about 0.01% to about 5% by weight of a preservative comprising methylparaben, propylparaben, and phenoxyethanol.

### Claim 51 (depends on 21)

The method of claim 21, wherein the composition is a cream.

### Claim 52 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition comprises, oxymetazoline HCI in an amount of about 1.0% by weight.

### Claim 53

A method of treating erythema, telangiectasia or inflammatory lesions associated with rosacea comprising topically administering a pharmaceutical composition comprising
about 1.0% by weight oxymetazoline HCl;
about 20% by weight of an emulsifier, wherein the emulsifier comprises polyethylene glycol stearate (PEG-6 stearate), polyethylene glycol 32 stearate (PEG-32 stearate), glycol stearate, cetostearyl alcohol, ceteareth-6, and ceteareth-25; and
about 23% of an emollient comprising anhydrous lanolin, medium chain triglycerides, diisopropyl adipate, and oleyl alcohol;
about 4% of a solvent;
about 0.05% of butylated hydroxytoluene;
about 0.01% of a disodium edetate;
about 0.52% of a buffer comprising sodium citrate dihyrate and anhydrous citric acid;
about 1.05% of a preservative comprising methylparaben, propylparaben, and phenoxyethanol;
wherein the composition is a cream;
wherein the ratio of the PEG-6 stearate, PEG-32 stearate and glycol stearate to the cetostearyl alcohol is about 1:1;
wherein the ratio of the emulsifier to the emollient is about 0.87:1; and
wherein the pH of the composition is about 4.5.
